US nod for Merck’s C.difficile antitoxin
The US Food and Drug Administration has cleared Merck’s Clostridium difficile (CDI) recurrence jab Zinplava after having extended the review period by three month.
Read More
Tag: C difficile
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
- ViiV Healthcare data show lower rates of steatotic liver disease after switching to Dovato
- Tremfya data show sustained remission in ulcerative colitis through 3 years
